VYNE Therapeutics (VYNE) Misses Q1 EPS by 20c
Tweet
Share
E-mailGet Alerts VYNE Hot Sheet
Join SI Premium – FREE
VYNE Therapeutics (NASDAQ: VYNE) reported Q1 EPS of ($0.20). Revenue for the quarter came in at $200 thousand.
For earnings history and earnings-related data on VYNE Therapeutics (VYNE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
- JPMorgan Downgrades PLDT Inc. (TEL:PM) (PHI) to Neutral
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
